IL33 and coronary artery disorder: Both inflammatory host response [11] and comorbidities such as heart failure (HF) and coronary artery disease (CAD) revealed augmented expressions of interleukin (IL)-33 and soluble suppression of tumorigenicity 2 (sST2) [12,13].